**Company Overview**

OncoSec Medical Incorporated is a biopharmaceutical company developing its investigational immunotherapy, TAVO, for the treatment of cancer. OncoSec Medical's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. In clinical trials to date, we have not observed significant safety issues of concern. Further, we have observed preliminary evidence of anti-tumor activity to suggest the potential of TAVO in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec’s lead program evaluating TAVO for the treatment of metastatic melanoma is currently in Phase 2 development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate TAVO in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches.

**OncoSec Medical Incorporated Announces Proposed Public Offering**

May 21 2019, 4:01 PM EDT

**OncoSec Granted Exclusive Worldwide Rights To A Patent Portfolio For The Combination Use Of IL-12 DNA With Checkpoint Inhibitors To Treat Cancer In Several Key Countries**

May 21 2019, 8:30 AM EDT

**OncoSec Announces 1-for-10 Reverse Stock Split**

May 20 2019, 12:45 PM EDT

**Stock Overview**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>Exchange</th>
<th>Market Cap</th>
<th>Last Price</th>
<th>52-Week</th>
</tr>
</thead>
<tbody>
<tr>
<td>ONCS</td>
<td>Nasdaq</td>
<td>264.04m</td>
<td>$4.00</td>
<td>$3.52 - $19.60</td>
</tr>
</tbody>
</table>

**Disclaimer**

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements.

All trademarks and brand name are the property of their respective companies.